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Abstract
Crohn’s disease (CD) is a chronic relapsing and remitting 
autoinflammatory disorder of the gastrointestinal 
tract that has many intestinal and extraintestinal 
complications. The purpose of treatment is long-term 
remission, reduction of complications, and improvement 
of patients’ quality of life. In many cases, this can be 
quite challenging and it is necessary to have a well 
thought out management strategy. We present the 
case of a 38-year-old woman with fistulizing CD that 
manifested as diffuse abdominal pain and bloody 
diarrhea accompanied by arthralgia. In addition, there 
were ulcerative lesions surrounded by cutaneous 
inflammation and erythema on her extremities, indicative 
of pyoderma gangrenosum. The patient was treated with 
high doses of parenteral methylprednisolone without 
any improvement and was started on adalimumab. A 
positive response to adalimumab therapy was observed: 
after 2 mo of therapy, the ulcerative skin lesion healed 
completely and the enterogastric fistula was closed after 
5 mo adalimumab treatment. Adalimumab might be a 
suitable initial as well as maintenance therapy in patients 
with complicated CD.
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INTRODUCTION
Crohn’s disease (CD) is characterized by fissuring 
ulcers and segmental transmural inflammation of  the 
gastrointestinal tract. The ileum is frequently involved in 
chronic inflammatory diseases; however, these can occur 
in any part of  the digestive tract, from mouth to anus. 
Fistulas are the major and most common complications 
of  the disease. The cumulative risk of  any kind of  
fistula is 33% after 10 years and 50% after 20 years from 
the first appearance of  the disease, as exemplified by a 
population-based study[1]. Although CD predominantly 
affects the gastrointestinal system, it is also associated 
with several extraintestinal manifestations. The most 
common extraintestinal disorders associated with 
inflammatory bowel disease (IBD) include dermatologic, 
ophthalmologic, musculoskeletal and hepatobiliary 
diseases; however, practically every organ system 
could be involved. These extraintestinal disorders can 
significantly contribute to morbidity and consequently 
impair the overall life quality of  the patient considerably 
more than bowel-related symptoms. 
Treatment is very complex and includes antibiotics 
and various immunomodulators. Surgery may be needed 
for therapy-refractory cases. The increasing number 
of  advanced biological treatments for IBD offers new 
possibilities for the management of  IBD associated with 
extraintestinal manifestations[2]. 
We report a case of  successful adalimumab usage 
for CD complicated by enterocutaneous fistula, which 
also constituted an effective alternative treatment for 
pyoderma gangrenosum.
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A 38-year-old woman presented with a 20-year history 
of  CD, numerous complications and frequent relapses. 
Previously she had undergone several corrective 
gastrointestinal surgeries for perirectal fistulas. She 
carried a stoma since 1997 following left hemicolectomy 
and Hartmann’s procedure. She continued to receive 
maintenance 5-aminosalycilate (mesalamine) and 
budesonide therapy. Corticosteroid therapy and 
combined antibiotic/antimycotic treatment were used 
intermittently for increased disease activity resulting in 
moderate clinical response. The patient was unable to 
tolerate azathioprine.
In February 2004, she developed erythema nodosum 
on her extremities, which was resolved by corticosteroid-
antibiotic treatment. The patient was referred to our 
department for further examination and management 
in November 2004, when she developed asymmetric 
oligoarthritis that responded well to treatment with a 
corticosteroid and maintenance methotrexate, resulting 
in remission for 6 mo. In 2005, the patient was treated 
with intravenous pulse cyclophosphamide for moderate 
to severe disease activity as a rescue therapy.
The patient remained in remission for 6 mo. In 
January 2007, she was admitted to our hospital again 
because of  increased weakness, mild ulcerative skin 
lesions, and abdominal pain with bloody diarrhea. 
Additionally, she had arthralgia but no fever. Her blood 
tests showed a white cell count of  8.97 × 109 cells/L, a 
platelet count of  289 × 109 cells/L, a C reactive protein 
level of  68.57 mg/L, a hematocrit of  36 and an increased 
erythrocyte sedimentation rate (64 mm/h). Immunologic 
evaluation did not show B-cell/immunoglobulin disorders 
or antibody positivity. Upon physical examination, she 
had some small, red papules on her extremities with 
ulcerations on their surface that were characterized by 
pyoderma gangrenosum (Figure 1). In addition, we also 
found diffuse abdominal tenderness and an abdominal 
mass located in the periumbilical region. Her urine 
and chest X-rays were normal. Abdominal computed 
tomography (CT) showed a moderately enlarged spleen 
as well as thickened and inflamed bowel walls that are 
characteristic of  CD (Figure 2). The inflamed bowels were 
surrounded by fat stranding, and CT also showed multiple 
enterocolic fistulas. Upper endoscopic examination 
revealed an enterogastric fistula from the corpus of  the 
stomach to the stoma. Surgical correction was not an 
option because the patient did not agree to surgery. The 
patient received infliximab (Remicade; Schering-Plough) 
therapy as well as maintenance methotrexate therapy but 
there was no significant improvement in her symptoms 
and in her test results. 
Following a failed course of  infliximab (because 
of  lack of  response), adalimumab (Humira; Abbott 
Laboratories) was proposed as an alternative treatment. 
Adalimumab was administered subcutaneously at 
a dose of  80 mg/wk for the first 2 wk followed by 
40 mg/wk afterwards. In addition, the patient was 
treated for a limited period with high doses of  parenteral 
methylprednisolone and a combined antibiotic treatment. 
After 2 mo of  therapy, the skin ulcers were completely 
healed. Subjective clinical improvement could be seen 
after 3 mo of  therapy. The patient did not experience 
any adverse effects. After 5 mo of  therapy contrast 
radiography of  the bowel passage showed significant 
improvement. A 3-4 cm long, narrow and blind fistula 
originating from the stomach could be seen but it was not 
connected to the bowel. Nevertheless, the duodenum and 
jejunum were moderately inflamed and the terminal ileum 
was intact without inflammatory signs.
DISCUSSION
Up until now the use of  adalimumab for fistulizing CD 
with extraintestinal manifestations has been reported in 
only a few cases. We reported a case of  a woman with 
CD complicated by fistulas and pyoderma gangrenosum. 
The patient was successfully treated with adalimumab.
Extraintestinal manifestations of  IBD can be 
diagnosed before, simultaneously with, or after the 
diagnosis of  IBD is made. These symptoms occur in 
21%-36% of  IBD cases. It is important to distinguish 
complications of  IBD from secondary diseases as 
they demand different and specialized therapies. The 
recognition of  symptoms can be difficult since these 
extraintestinal symptoms can also be the primary 
manifestations of  IBD[3,4]. 
The connection between different extraintestinal 
symptoms and IBD is unclear. The shared and unique 
epitopes in the human colon, eye, joint and biliary 
epithelium may suggest an immune mediated process.
Pyoderma gangrenosum is one of  these inflamma-
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Figure 1  Small, red 
papules on the extremi-
ties with ulcerations.
Figure 2  Enterogastric 
fistula from the corpus 
o f  t h e  s t o m a c h  t o 
stoma on abdominal 
computed tomography 
(white arrow).←
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tory cutaneous manifestations and it is independent of  
disease activity. This ulcerative cutaneous condition can 
either be associated with systemic inflammatory diseases 
(in at least 50% of  cases) or it can occur alone. The di-
agnosis is made by excluding other causes of  cutaneous 
ulcerations that are similar in appearance, including in-
fection, malignancy, vasculitis, collagen vascular diseases, 
diabetes, and trauma. Treatment is relatively difficult. 
Currently, systemic immunosuppressants, often pred-
nisone, are the mainstay of  therapy. Long-term therapy 
with these agents is often required and can expose pa-
tients to possible adverse effects. 
The treatment of  IBD with extraintestinal manifesta-
tion has advanced in parallel to our increasing understand-
ing of  its pathomechanism[5-9]. One of  the most well 
recognized proinflammatory mediators involved in the 
pathogenesis of  IBD is tumor necrosis factor α (TNF-α). 
It is known that high levels of  TNF-α have been associ-
ated with the development of  intestinal inflammation in 
CD. The current evidence suggests that TNF-α blocking 
agents such as infliximab, adalimumab, and certolizumab 
pegol are effective maintenance therapy in CD. TNF-α 
blocking agents bind with TNF-α molecules thereby neu-
tralizing the biological activity of  TNF-α, resulting in the 
reduction of  intestinal inflammation.
On other hand, treatment strategies for fistulizing 
CD are usually controversial. External fistulas are more 
responsive to medical therapy than internal fistulas in 
patients with CD. Combined treatment with antibiotics 
and immunomodulators may be a suitable initial therapy 
for CD patients with external fistulas. TNF-α blocking 
agents can also be used as an additional therapy in the 
treatment of  corticosteroid dependent, refractory cases 
or in complicated extraintestinal manifestations[10]. 
This case report demonstrates the potential efficacy 
of  adalimumab in the management of  complicated 
fistulizing CD and/or pyoderma gangrenosum. Further 
studies into the use of  adalimumab in this patient 
subgroup with CD are warranted. 
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